PCSA vs NUVB

Analysts rate Processa Pharmaceuticals, Inc.

(PCSA) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Nuvation Bio Inc.

(NUVB) delivered a total return of -58. 3%, compared to -97. 9% for Processa Pharmaceuticals, Inc. (PCSA). Over 10 years, the gap is even starker: NUVB returned -52. 1% versus PCSA's -94. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Processa Pharmaceuticals, Inc.

(PCSA) is the lower-risk stock at 1. 81β versus Nuvation Bio Inc. 's 1. 97β — meaning NUVB is approximately 9% more volatile than PCSA relative to the S&P 500.

On earnings-per-share growth, the picture is similar: Processa Pharmaceuticals, Inc.

grew EPS 89. 3% year-over-year, compared to 71. 6% for Nuvation Bio Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Processa Pharmaceuticals, Inc.

(PCSA) is the more profitable company, earning 0. 0% net margin versus -325. 3% for Nuvation Bio Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PCSA leads at 0. 0% versus -338. 7% for NUVB. At the gross margin level — before operating expenses — NUVB leads at 86. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Processa Pharmaceuticals, Inc.

(PCSA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Nuvation Bio Inc. (NUVB) carries a higher beta of 1. 97 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PCSA: -94. 1%, NUVB: -52. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PCSA is a small-cap quality compounder stock; NUVB is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.